A detailed history of Victory Capital Management Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 12,654 shares of NTLA stock, worth $191,328. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,654
Previous 12,225 3.51%
Holding current value
$191,328
Previous $273,000 4.76%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$19.72 - $27.36 $8,459 - $11,737
429 Added 3.51%
12,654 $260,000
Q2 2024

Aug 05, 2024

SELL
$20.02 - $27.22 $3,483 - $4,736
-174 Reduced 1.4%
12,225 $273,000
Q1 2024

May 03, 2024

BUY
$23.82 - $32.8 $13,505 - $18,597
567 Added 4.79%
12,399 $341,000
Q4 2023

Feb 05, 2024

SELL
$23.16 - $32.34 $358,609 - $500,752
-15,484 Reduced 56.68%
11,832 $360,000
Q3 2023

Nov 06, 2023

BUY
$31.62 - $45.78 $14,861 - $21,516
470 Added 1.75%
27,316 $863,000
Q2 2023

Jul 27, 2023

SELL
$34.58 - $46.03 $7,261 - $9,666
-210 Reduced 0.78%
26,846 $1.09 Million
Q1 2023

May 02, 2023

BUY
$33.3 - $44.82 $58,641 - $78,928
1,761 Added 6.96%
27,056 $1.01 Million
Q4 2022

Feb 10, 2023

BUY
$33.21 - $62.69 $2,656 - $5,015
80 Added 0.32%
25,295 $882,000
Q4 2022

Feb 09, 2023

SELL
$33.21 - $62.69 $20,357 - $38,428
-613 Reduced 2.37%
25,215 $879,000
Q3 2022

Nov 02, 2022

SELL
$53.92 - $71.7 $131,403 - $174,732
-2,437 Reduced 8.62%
25,828 $1.45 Million
Q2 2022

Aug 01, 2022

SELL
$38.49 - $76.21 $21.5 Million - $42.7 Million
-559,666 Reduced 95.19%
28,265 $1.46 Million
Q1 2022

May 04, 2022

SELL
$58.27 - $118.99 $2.31 Million - $4.71 Million
-39,566 Reduced 6.31%
587,931 $42 Million
Q4 2021

Feb 07, 2022

SELL
$100.76 - $138.36 $14.3 Million - $19.6 Million
-141,959 Reduced 18.45%
627,497 $74.2 Million
Q3 2021

Nov 02, 2021

BUY
$132.37 - $176.78 $49.8 Million - $66.5 Million
375,933 Added 95.53%
769,456 $103 Million
Q2 2021

Aug 03, 2021

BUY
$60.88 - $161.91 $21.5 Million - $57.2 Million
353,428 Added 881.48%
393,523 $63.7 Million
Q1 2021

May 04, 2021

BUY
$46.59 - $83.68 $209,794 - $376,811
4,503 Added 12.65%
40,095 $3.22 Million
Q4 2020

Feb 01, 2021

SELL
$18.83 - $63.53 $33,762 - $113,909
-1,793 Reduced 4.8%
35,592 $1.94 Million
Q3 2020

Nov 09, 2020

BUY
$17.47 - $24.93 $653,115 - $932,008
37,385 New
37,385 $743,000
Q2 2020

Aug 07, 2020

SELL
$11.14 - $22.87 $60,412 - $124,024
-5,423 Closed
0 $0
Q1 2020

May 04, 2020

SELL
$9.44 - $15.58 $29,179 - $48,157
-3,091 Reduced 36.3%
5,423 $66,000
Q4 2019

Feb 06, 2020

BUY
$10.43 - $17.67 $32,791 - $55,554
3,144 Added 58.55%
8,514 $125,000
Q4 2019

Feb 04, 2020

BUY
$10.43 - $17.67 $3,640 - $6,166
349 Added 6.95%
5,370 $64,000
Q3 2019

Nov 12, 2019

BUY
$13.07 - $18.51 $65,624 - $92,938
5,021 New
5,021 $67,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.15B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.